Aktuellt
SENASTE
Redeye briefly comments on Fluoguide’s Q1 2022 report. We believe the company has executed some important milestones during the first five months of 2022, raising capital and presenting solid FG001 safety and efficacy data from part 1 of its phase I/II trial in high-grade glioma. We see top-line data from the second part (phase IIb) of Fluoguide’s phase I/II trial in high-grade glioma and its phase II trial in lung cancer as the main remaining catalysts for the stock in 2022.
LÄS MER
